THE HAGUE, The Netherlands, June 30, 2025 (GLOBE NEWSWIRE) -- In a strategic move to improve patient outcomes in breast cancer, Affidea, a leading pan-European provider of community-based polyclinics, specialist services and advanced diagnostics, is proud to announce that it has selected b-rayZ, a leader in AI-powered breast imaging solutions, as its preferred AI partner for breast imaging.
EHR industry is booming due to rising digitalization, regulatory mandates, and demand for streamlined patient data access. Key players like Epic Systems, Cerner (Oracle), and Allscripts dominate with innovative, cloud-based solutions. Growing investments in telehealth and AI integration continue to accelerate market expansion across hospitals and ambulatory care settings.
EHR industry is booming due to rising digitalization, regulatory mandates, and demand for streamlined patient data access. Key players like Epic Systems, Cerner (Oracle), and Allscripts dominate with innovative, cloud-based solutions. Growing investments in telehealth and AI integration continue to accelerate market expansion across hospitals and ambulatory care settings.
− Results show delivery of high radiation doses to tumours compared with normal organs.− Observed normal organ absorbed dosimetry results may allow administration of...
− Results show delivery of high radiation doses to tumours compared with normal organs.− Observed normal organ absorbed dosimetry results may allow administration of...
NEW HAVEN, Conn., June 20, 2025 /PRNewswire-HISPANIC PR WIRE/ -- Yale School of Medicine (YSM) announces the launch of the Yale Biomedical Imaging Institute, a...
NEW HAVEN, Conn., June 20, 2025 /PRNewswire/ -- Yale School of Medicine (YSM) announces the launch of the Yale Biomedical Imaging Institute, a cross-disciplinary hub that...
PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.3,4 A final decision on the approval in the European Union is expected in the coming months.
MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces five abstract presentations and two satellite symposia featuring its developmental theranostic programs and commercial products at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting being held in New Orleans, Louisiana (U.S.) from June 21 – 24.